Johnson & Johnson reports that its pioneering RIPTAC™ molecule, JNJ-6143, has a 75% tumor remission rate in advanced prostate cancer.

Zhitongcaijing · 2d ago
Johnson & Johnson reports that its pioneering RIPTAC™ molecule, JNJ-6143, has a 75% tumor remission rate in advanced prostate cancer.